Recent acquisitions in the treatement of chronic immune-mediated polyneuropathies;Acquisitions récentes dans le traitement des polyneuropathies dysimmunitaires chroniques

Revue Neurologique

Volumn 160, Issue 2, 2004, Pages 205-210

  Leger J M ^a   Viala, K ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN;

CHRONIC DISEASE; CONFERENCE PAPER; DRUG EFFICACY; ELECTROPHYSIOLOGY; HISTOPATHOLOGY; HUMAN; IMMUNE MEDIATED INJURY; IMMUNOCHEMISTRY; MONOCLONAL IMMUNOGLOBULINEMIA; MOTOR NEUROPATHY; PLASMAPHERESIS; POLYNEUROPATHY;

EID: 1542284193     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-3787(04)70892-9     Document Type: Conference Paper

References (67)

1. AD Hoc SUBCOMMITTEE OF THE AMERICAN ACADEMY OF NEUROLOGY AIDS TASK FORCE. (1991). Research criteria for the diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology, 41: 617-618.
2. AUSTIN JH. (1958). Recurrent polyneuropathies and their corticosteroid treatment. Brain, 81: 157-192.
3. AZULAY JP, BLIN O, POUGET J et al. (1994). Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebocontrolled study. Neurology, 44: 429-432.
4. BLUME G, PESTRONK A, GOODNOUGHT LT. (1995). Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchanges and IV cyclophosphamide. Neurology, 45: 1577-1580.
5. BOUCHE P, MOULONGUET A, YOUNES-CHENNOUFI A et al. (1995). Multifocal motor neuropathy associated with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry, 59: 38-44.
6. BRIANI C, BRANNAGAN TH III, TROJABORG W, LATOV N. (1996). Chronic inflammatory demyelinating polyneuropathy. Neuromusc Disord, 6: 311-325.
7. CHASSANDE B, LĖGER JM, BEN YOUNES-CHENNOUFI A et al. (1998). Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve, 21: 55-62.
8. CHIO A, PLANO F and the PARCIDP. (2002). Chronic inflammatory demyelinating polyneuropathy (CIDP): an epidemiologic study in Italy. Neurology 58 (Suppl 3) A185.
9. CHIN RL, SHERMAN WH, SANDER HW, HAYS AP, LATOV N. (2003). Etanercept (Enbrel®) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci, 210: 19-21.
10. CLAUS D, SPECHT S, ZIESCHANG M. (2000). Plasmapheresis in multifocal motor neuropathy: a case report. J Neurol Neurosurg Psychiatry, 68: 533-535.
11. DALAKAS MC, RICHARD HQ, FARRER RG et al. (1996). A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol. 40: 792-795.
12. DI TROIA A, CARPO A, MEUCCI N et al. (1999). Clinical features and anti-neural activity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance. J Neurol Sci, 164: 64-71.
13. DYCK PJ, LAIS AC, OHTA M, BASTRON JA, OKAZAKI H, GROOVER RV. (1975). Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc, 50: 621-651.
14. DYCK PJ, O'BRIEN PC, OVIATT KD et al. (1982). Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol, 11: 136-141.
15. DYCK PJ, DAUBE J, O'BRIEN PC et al. (1986). Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med, 314: 461-465.
16. DYCK PJ, LITCHY WJ, KRATZ KM et al. (1994). A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyneuropathy. Ann Neurol, 36: 838-845.
17. FEDERICO P, ZOCHODNE DW, HAHN AF, BROWN WF, FEASBY TE. (2000). Multifocal motor neuropathy improved by IVIg. Randomized, double-blind, placebo-controlled study. Neurology, 55: 1256-1262.
18. FRANSSEN H, VERMEULEN M, JENNEEENS FGI. (1997). Chronic inflammatory demyelinating neuropathies. In Emery AEH (ed). Diagnostic criteria for neuromuscular disorders, 2nd ed., London, Royal Society of Medicine Press, pp 53-59.
19. FUKASE M, TSUNEMATSU T, NISHITANI H, IMURA H, MATSUOKA H. (1968). Report of a case of solitary plasmocytoma in the abdomen presenting polyneuropathy and endocrinal disorders. Clinical Neurology (Tokyo), 9: 657.
20. GORSON KC, ROPPER AH, WEINBERG DH, WEINSTEIN R.(2002). Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol, 59: 7766-7772.
21. HADDEN RDM, SHARRACK B, BENSA S, SOUDAIN SE, HUGHES RAC. (1999). Randomized trial of interferon bêta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology, 53: 57-61.
22. HAHN AF, BOLTON CF, PILLAY N et al. (1996). Plasma exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain, 119: 1055-1066.
23. HAHN AF, BOLTON CF, ZOCHODNE D, FEASBY TE. (1996). Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain, 119: 1067-1077.
24. HERMOSILLA E, LAGUENY A, VITAL C et al. (1996). Peripheral neuropathy associated with monoclonal IgG of undetermined significance. Clinical, electrophysiologic, pathologic and therapeutic study of 14 cases. J Periph Nerv Syst, 1: 139-148.
25. HUGHES RAC, BENSA S, WILLISON H et al. (2001). Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyneuropathy. Ann Neurol, 50: 195-201.
26. HUGHES RAC. (2002). Systematic review of treatment for chronic inflammatory demyelinating neuropathy. Rev Neurol, 158: 6S32-6S36.
27. KUNTZER T, RADZIWILL AJ, LETTRY-TROUILLAT R et al. (1999). Interferon bêta 1a in chronic inflammatory demyelinating polyneuropathy. Neurology, 53: 1364-1365.
28. LÉGER JM, BEN YOUNES-CHENNOUFI A, CHASSANDE B et al. (1994). Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry, 57(Supplement): 46-49.
29. LÉGER JM, HAYES M. (2001). Neuropathies associated with monoclonal gammopathy. In D Cros (ed). Peripheral neuropathy: a practical approach to diagnosis and management. Lipinkott Williams & Wilkins, pp 109-121.
30. LÉGER JM, CHASSANDE B, MUSSET L, MEININGER V, BOUCHE P, BAUMANN N. (2001). Intravenous immunoglobulin therapy in multifocal motor neuropathy. A double-blind, placebo-controlled, study. Brain, 124: 145-153.
31. LEWIS RA, SUMNER AJ, BROWN MJ, ASBURY AK. (1982). Multifocal demyelinating neuropathy with persistent conduction block. Neurology, 32: 958-964.
32. LUNN MPT, MANJI H, CHOUDHARY PP et al. (1999). Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry, 66: 269-271.
33. MAGY L, CHASSANDE B, MAISONDX T, BOUCHE P, VALLAT JM, LĖGER JM et al. (2003). Polyneuropathy associated with IgG/IgA monoclonal gammopathy: a clinical and electrophysiological study of 15 cases. Eur J Neurol, 10: 677-685.
34. MARIETTE X, CHASTANG C, CLAVELOU P, LOUBOUTIN JP, LÉGER JM, BROUET JC. (1997). A randomized clinical trial comparing alpha interferon and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM gammopathy. J Neurol Neurosurg Psychiatry, 63: 28-34.
35. MARIETTE X, BROUET JC, CHEVRET S et al. (2000). A randomized double-blind trial versus placebo do not confirm the benefit of alpha interferon in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry, 69: 274-283.
36. MCLEOD JG, POLLARD JD, MACASKILL P et al. (1999). Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol, 46: 910-913.
37. MEHNDIRATA MM, HUGHES RAC. (2001). Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (Cochrane Review). Cochrane Database Syst Rev.3 Oxford: Update Software.
38. MENDELL JR, BAROHN RJ, FREIMER ML et al. (2001). Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology, 56: 445-449.
39. MERKIES IS, SCHMITZ PI, VAN DER MÉCHÉ FG et al. (2000). Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. INCAT Group. Neurology, 54: 943-949.
40. MERKIES IS, SCHMITZ PI, VAN DER MÉCHÉ FG et al. (2002a). Psychometric evaluation of a new handicap scale in immune mediated polyneuropathies. Muscle Nerve, 25: 370-377.
41. MERKIES IS, SCMITZ PI, VAN DER MÉCHÉ FG et al. (2002b). Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry, 72: 596-601.
42. MOLENAAR DSM, VAN DOORN PA, VERMEULEN M. (1997). Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. J Neurol Neurosurg Psychiatry, 62: 388-390.
43. MOWZOON N, SUSSMAN A, BRADLEY WG. (2001). Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci, 185: 119-122.
44. NICOLAS G, MAISONOBE T, LE FORESTIER N, LÉGER JM, BOUCHE P. (2002). Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve, 25: 26-30.
45. NOBILE-ORAZIO E, MEUCCI N, BALDINI L et al. (2000). Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain, 123: 710-717.
46. NOBILE-ORAZIO E, CARPO M. (2001). Neuropathy and monoclonal gammopathy. Curr Opin Neurol, 14: 615-620.
47. NOBILE-ORAZIO E. (2001). Multifocal motor neuropathy. J Neuroimmunol, 115: 4-18.
48. NOBILE-ORAZIO E, CAPPELLARI A, MEUCCI N et al. (2002). Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry, 6: 761-766.
49. OKSENHENDLER E, CHEVRET S, LÉGER JM, LOUBOUTIN JP, BUSSEL A, BROUET JC. (1995). for the IgM-associated polyneuropathy study group. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. J Neurol Neurosurg Psychiatry, 59: 243-247.
50. PESTRONK A, FLORENCE J, MILLER T et al. (2003). Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry, 74: 485-489.
51. RENAUD S, GREGOR M, FUHR P et al. (2003). Rituximab in the treatment of anti-MAG associated polyneuropathy. Muscle Nerve, 27: 611-615.
52. SABATELLI M, MADIA F, MIGNOGNA T et al. (2001). Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol, 248: 772-777.
53. SAID G. (2002). Chronic inflammatory demyelinating polyneuropathy. J Neurol, 249: 245-253.
54. SAPERSTEIN DS, KATZ JS, AMATO AA, BAROHN RJ. (2001). Clinical spectrum of chronic inflammatory demyelinating polyneuropathies. Muscle Nerve, 24: 311-324.
55. 79TH ENMC INTERNATIONAL WORKSHOP. (2001). Multifocal motor neuropathy 14-15 april 2000, Hilversum, the Netherlands. Neuromuscul Disord, 11: 309-314.
56. TAYLOR BV, WRIGHT RA, HARPER CM, DYCK PJ. (2000). Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve, 23: 900-908.
57. TROJABORG W. (1998). Acute and chronic neuropathies: new aspects of Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy, an overview and an update. Electroencephalogr Clin Neurophysiol, 107: 303-316.
58. UMAPATHI T, HUGHES RAC, NOBILE-ORAZIO E, LÉGER JM. (2002). Immunosuppressive treatment for multifocal motor neuropathy (Cochrane Review). In The Cochrane Library, issue 2. Oxford: Update Software Ltd; http://www.update-software.com/abs-tracts/ab003217.htm
59. VALLAT JM, JAUBERTEAU MO, BORDESSOULE D et al. (1996). Link between peripheral neuropathy and monoclonal dysglobulinemia: a study of 66 cases. J Neurol Sci, 137: 124-130.
60. VALLAT JM, TABARAUD F, MAGY L et al. (2003a). Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: evaluation of 8 cases. Muscle Nerve, 27: 478-485.
61. VALLAT JM, HAHN AF, LÉGER JM et al. (2003b). Interferon bêta-1a as investigational treatment for CIDP. Neurology, 60(8 Suppl 3): 23-28.
62. VAN DEN BERG LH, KERKHOFF H, OEY PI et al. (1995). Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double-blind, placebo-controlled study. J Neurol Neurosurg Psychiatry, 59: 248-252.
63. VAN DEN BERG-VOS RM, FRANSSEN H, WOKKE J, VAN ES HW, VAN DEN BERG LH. (2000). Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann Neurol, 48: 919-926.
64. VAN DEN BERG-VOS RM, FRANSSEN H, VISSER J et al. (2002). Disease severity in multifocal motor neuropathy and its association with the response to treatment. J Neurol, 3: 330-336.
65. VAN DOORN PA, VERMEULEN M, BRAND A, MULDER PGH, BUSCH HFM. (1991). Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol, 48: 217-220.
66. VAN DOORN PA, GARSSEN MPJ. (2002). Treatment of immune neuropathies. Curr Opin Neurol, 15: 623-631.
67. WILSON HC, LUNN MPT, SCHEY S, HUGHES RAC. (1999). Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry, 66: 575-580.